Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

Immatics N.V. Warrants · IMTXW

IMTXWNASDAQWarrantHistorical · closed Jun 30, 2025CIK 1809196Updated Nov 21, 2026

Company: Immatics N.V. →

Name history
Immatics B.V. · through Jul 8, 2020
Current security for this SEC filerIMTX · NASDAQ

IMTXW price & chart

Provider market data
Historical security

This listing closed Jun 30, 2025. Live provider charts are shown only for current listings.

Current security: IMTX

About the company

Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.

6-K · 2026-11-10 · 0001193125-26-454401

Company description from the cited filing.

In the news

No coverage from other publishers is available.

Financials

FY 2025 · EUR
Revenue— · FY 2025
Net income— · FY 2025
Assets—EUR · FY 2025
Cash— · FY 2025
Operating income-182,016,000EUR · FY 2025
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

Diluted EPS-1.61EUR/shares · FY 2025
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemQ4 2024Q2 2025Q2 2024Q2 2023Q2 2022Q2 2021Q2 2020FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Profit or LossEUR—-70,348,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

-17,992,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

-24,610,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

-13,980,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

-26,534,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

-21,326,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

-196,447,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

15,218,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

-96,994,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

37,514,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

Additional Financial Items
AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR———————-242,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

-1,764,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

-2,982,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

-429,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseEUR—12,780,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

10,128,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

9,358,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

8,683,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

8,271,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

10,076,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

51,184,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

46,449,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

38,198,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

36,124,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

InterestPaidClassifiedAsOperatingActivitiesEUR———————946,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

886,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

290,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

695,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

InterestReceivedClassifiedAsOperatingActivitiesEUR———————26,817,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

15,605,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

10,167,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

1,649,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR———————2,959,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

2,012,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

3,849,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

2,843,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

ProceedsFromIssuingSharesEUR———————107,310,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

343,010,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

90,404,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

134,484,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodEUR———————549,859,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

314,440,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

414,744,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

12,695,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR————————2,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

150,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

52,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR———————247,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

208,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

158,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

477,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2024Q2 2025Q2 2024Q2 2023Q2 2022Q2 2021Q2 2020FY 2025FY 2024FY 2023FY 2022
Additional Financial Items
ApplicableTaxRatenumber—0.3
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

0.3
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

0.3
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

0.29
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

0.29
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

0.29
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

0.31
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

0.3
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

0.3
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

0.3
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

BasicEarningsLossPerShareEUR/shares—-0.58
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

-0.17
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

-0.32
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

-0.22
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

-0.42
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

—-1.61
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

0.14
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

-1.2
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

0.56
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

CurrentTaxExpenseIncomeEUR—0
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

170,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

————9,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

7,790,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

-12,774,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

DeferredTaxExpenseIncomeEUR—-1,001,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

-30,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

————-1,998,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

-1,662,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

——
DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR———————100,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

———
DepreciationRightofuseAssetsEUR———————3,231,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

3,417,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

3,723,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

-3,620,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

DilutedEarningsLossPerShareEUR/shares—-0.58
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

-0.17
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

-0.32
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

-0.22
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

-0.42
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

—-1.61
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

0.14
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

-1.2
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

0.55
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

EmployeeBenefitsExpenseEUR———————103,073,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

89,342,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

76,325,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

-73,205,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR—4,141,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

4,308,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

5,513,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

-5,560,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

7,965,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

8,691,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

15,015,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

17,642,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

20,705,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

-22,570,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedEUR———————109,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

85,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

86,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

—
ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR—————————1,548,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

-190,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

FinanceCostsEUR—22,776,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

305,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

1,144,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

407,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

629,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

2,164,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

36,666,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

1,321,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

-7,040,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

8,279,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

FinanceIncomeEUR—4,421,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

9,665,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

3,954,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

7,015,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

213,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

437,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

18,516,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

44,018,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

13,850,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

9,416,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseEUR—12,780,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

10,128,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

9,358,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

8,683,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

8,271,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

10,076,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

51,184,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

46,449,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

38,198,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

36,124,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

IncomeTaxExpenseContinuingOperationsEUR—-1,001,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

140,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

0
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

1,145,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

0
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

0
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

-1,989,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

6,128,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

4,522,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

InterestExpenseEUR—244,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

226,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

206,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

376,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

140,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

81,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

946,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

886,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

831,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

1,038,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

OtherEmployeeExpenseEUR———————400,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

300,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

200,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

100,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

OtherFinanceCostEUR—22,776,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

305,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

1,144,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

407,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

——36,666,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

1,321,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

7,040,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

8,279,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

OtherIncomeEUR—22,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

25,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

6,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

27,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

26,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

86,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

4,734,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

78,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

1,139,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

26,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

PostemploymentBenefitExpenseDefinedContributionPlansEUR———————2,200,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

1,600,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

500,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

900,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

ProfitLossAttributableToOwnersOfParentEUR——-17,992,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

——-26,534,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2021-04-01 to 2021-06-30

-21,043,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

———37,514,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

ProfitLossBeforeTaxEUR—-71,349,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

-17,852,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

-24,610,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

-12,835,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

-26,534,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

-21,326,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

-198,436,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

21,346,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

-96,994,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

42,036,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

ProfitLossFromOperatingActivitiesEUR—-53,127,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

-26,564,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

-14,315,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

-16,657,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

-23,396,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

-19,599,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

-182,016,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

-38,615,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

-101,725,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

29,954,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

ResearchAndDevelopmentExpenseEUR—45,106,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2025-04-01 to 2025-06-30

35,216,000
Source

6-K · 2025-08-13 · 0001193125-25-179419

2024-04-01 to 2024-06-30

27,317,000
Source

6-K · 2024-08-13 · 0001193125-24-199384

2023-04-01 to 2023-06-30

25,216,000
Source

6-K · 2023-08-17 · 0001193125-23-214704

2022-04-01 to 2022-06-30

20,340,000
Source

6-K · 2022-08-09 · 0001193125-22-215577

2021-04-01 to 2021-06-30

16,505,000
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

183,832,000
Source

20-F · 2026-03-05 · 0001193125-26-092529

2025-01-01 to 2025-12-31

148,079,000
Source

20-F · 2025-03-27 · 0000950170-25-045724

2024-01-01 to 2024-12-31

118,663,000
Source

20-F · 2024-03-21 · 0001193125-24-073296

2023-01-01 to 2023-12-31

106,779,000
Source

20-F · 2023-03-22 · 0001193125-23-076227

2022-01-01 to 2022-12-31

NetForeignExchangeLoss——————
Source

6-K · 2021-08-10 · 0001193125-21-241250

2021-04-01 to 2021-06-30

—
Source

6-K · 2021-08-10 · 0001193125-21-241250

2020-04-01 to 2020-06-30

————
ProfitLossAttributableToNoncontrollingInterests———————
Source

6-K/A · 2021-10-28 · 0001193125-21-310430

2020-04-01 to 2020-06-30

————

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

imtx-ex99_1.htm · 6-K · 2026-11-10

Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month period ended September 30, 2026, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented in euros. All references in this interim report to “$,” and “U.S. dollars” mean U.S. dollars a…

6-K · 2026-11-10 · 0001193125-26-454401

Read attachment ↗
imtx-ex99_2.htm · 6-K · 2026-11-10

Exhibit 99.2 PRESS RELEASE Immatics Announces Third Quarter 2026 Financial Results and Business Update • Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint • SUPRAME topline data disclosure remains expected in H1 2027, followed by BLA submission in 2027 • IMA203CD8 PRAME Cell Therapy: Updated Phase 1 data presented at ESMO Congress 2026 s…

6-K · 2026-11-10 · 0001193125-26-454401

Read attachment ↗
d153472dex41.htm · 6-K · 2026-08-26

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES IMMATICS N.V. Number of Ordinary Shares: [_________] (subject to adjustment) Warrant No. [___] Date of Issuance: [___], 2026 (such date, the “Original Issue Date”) Immatics N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered as…

6-K · 2026-08-26 · 0001193125-26-368946

Read attachment ↗
d153472dex991.htm · 6-K · 2026-08-26

Exhibit 99.1 PRESS RELEASE Immatics Announces $150 Million Underwritten Offering Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purch…

6-K · 2026-08-26 · 0001193125-26-368946

Read attachment ↗
imtx-ex99_1.htm · 6-K · 2026-08-18

Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and six-month period ended June 30, 2026, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented in euros. All references in this interim report to “$,” and “U.S. dollars” mean U.S. dollars and all…

6-K · 2026-08-18 · 0001193125-26-354715

Read attachment ↗
imtx-ex99_2.htm · 6-K · 2026-08-18

Exhibit 99.2 PRESS RELEASE Immatics Announces Second Quarter 2026 Financial Results and Business Update • Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint; aggregate PFS events (progression or death) occurring more slowly than originally modeled • Company plans to proceed directly to a streamlined final analysis for the primary endp…

6-K · 2026-08-18 · 0001193125-26-354715

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.